Cargando…

Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs

Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women. Traditionally, topical minoxidil and oral finasteride have been the standard of care yielding mixed results. New treatments such as Low-Level Laser Therapy (LLLT), microneedling, platelet-rich plasma (PRP), and other...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Michael, Abdin, Rama, Gaumond, Simonetta I, Issa, Naiem T, Jimenez, Joaquin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239632/
https://www.ncbi.nlm.nih.gov/pubmed/37284568
http://dx.doi.org/10.2147/CCID.S385861
_version_ 1785053529597018112
author Kaiser, Michael
Abdin, Rama
Gaumond, Simonetta I
Issa, Naiem T
Jimenez, Joaquin J
author_facet Kaiser, Michael
Abdin, Rama
Gaumond, Simonetta I
Issa, Naiem T
Jimenez, Joaquin J
author_sort Kaiser, Michael
collection PubMed
description Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women. Traditionally, topical minoxidil and oral finasteride have been the standard of care yielding mixed results. New treatments such as Low-Level Laser Therapy (LLLT), microneedling, platelet-rich plasma (PRP), and others have been extensively studied in the literature, and the purpose of this review is to provide a comprehensive discussion of the latest treatment methods and their efficacy in treating AGA. Novel therapies such as oral minoxidil, topical finasteride, topical spironolactone, botulinum toxin, and stem cell therapy offer interesting alternatives to standard of care therapies for patients. In this review, we present data from recent studies on the clinical efficacy of these treatments. Furthermore, as new treatments have emerged, clinicians have tested combination therapies to assess whether there may be a synergistic relationship between multiple modalities. While there has been a great increase in the treatments available for AGA, the quality of evidence varies greatly and there is still a great need for randomized double blinded clinical trials to adequately assess the clinical efficacy of some treatments. While PRP and LLLT have demonstrated encouraging results, standardized treatment protocols are needed to adequately inform clinicians on how to use such therapies. Given the abundance of new therapeutic options, clinicians and patients must weigh the benefits and risks of each treatment option for AGA.
format Online
Article
Text
id pubmed-10239632
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102396322023-06-05 Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs Kaiser, Michael Abdin, Rama Gaumond, Simonetta I Issa, Naiem T Jimenez, Joaquin J Clin Cosmet Investig Dermatol Review Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women. Traditionally, topical minoxidil and oral finasteride have been the standard of care yielding mixed results. New treatments such as Low-Level Laser Therapy (LLLT), microneedling, platelet-rich plasma (PRP), and others have been extensively studied in the literature, and the purpose of this review is to provide a comprehensive discussion of the latest treatment methods and their efficacy in treating AGA. Novel therapies such as oral minoxidil, topical finasteride, topical spironolactone, botulinum toxin, and stem cell therapy offer interesting alternatives to standard of care therapies for patients. In this review, we present data from recent studies on the clinical efficacy of these treatments. Furthermore, as new treatments have emerged, clinicians have tested combination therapies to assess whether there may be a synergistic relationship between multiple modalities. While there has been a great increase in the treatments available for AGA, the quality of evidence varies greatly and there is still a great need for randomized double blinded clinical trials to adequately assess the clinical efficacy of some treatments. While PRP and LLLT have demonstrated encouraging results, standardized treatment protocols are needed to adequately inform clinicians on how to use such therapies. Given the abundance of new therapeutic options, clinicians and patients must weigh the benefits and risks of each treatment option for AGA. Dove 2023-05-31 /pmc/articles/PMC10239632/ /pubmed/37284568 http://dx.doi.org/10.2147/CCID.S385861 Text en © 2023 Kaiser et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Kaiser, Michael
Abdin, Rama
Gaumond, Simonetta I
Issa, Naiem T
Jimenez, Joaquin J
Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title_full Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title_fullStr Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title_full_unstemmed Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title_short Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
title_sort treatment of androgenetic alopecia: current guidance and unmet needs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239632/
https://www.ncbi.nlm.nih.gov/pubmed/37284568
http://dx.doi.org/10.2147/CCID.S385861
work_keys_str_mv AT kaisermichael treatmentofandrogeneticalopeciacurrentguidanceandunmetneeds
AT abdinrama treatmentofandrogeneticalopeciacurrentguidanceandunmetneeds
AT gaumondsimonettai treatmentofandrogeneticalopeciacurrentguidanceandunmetneeds
AT issanaiemt treatmentofandrogeneticalopeciacurrentguidanceandunmetneeds
AT jimenezjoaquinj treatmentofandrogeneticalopeciacurrentguidanceandunmetneeds